Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease
2010 (English)In: Clinical neuropharmacology, ISSN 0362-5664, E-ISSN 1537-162X, Vol. 33, no 5, 260-264 p.Article in journal (Refereed) Published
Pridopidine shows promise as a treatment for some of the symptoms of HD. In this small-scale study, the most notable effect was improvement in voluntary motor symptoms. Larger, longer-term trials are warranted.
Place, publisher, year, edition, pages
2010. Vol. 33, no 5, 260-264 p.
ACR16, dopaminergic stabilizer, Huntington's disease, pridopidine, randomized clinical trial
IdentifiersURN: urn:nbn:se:umu:diva-42294DOI: 10.1097/WNF.0b013e3181ebb285PubMedID: 20616707OAI: oai:DiVA.org:umu-42294DiVA: diva2:409089